Development of a high-throughput screen for inhibitors of epstein-barr virus EBNA1

Journal of Biomolecular Screening

Volumn 15, Issue 9, 2010, Pages 1107-1115

  Thompson, Scott ^a   Messick, Troy ^b   Schultz, David C ^a   Reichman, Melvin ^c   Lieberman, Paul M ^a  

^a WISTAR INSTITUTE   (United States)

^b Vironika   (United States)

^c LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

anti infective drugs; antiviral; EBNA1; Epstein Barr virus; fluorescence polarization

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; EPSTEIN BARR VIRUS ANTIGEN 1; IMMEDIATE EARLY PROTEIN BZLF1; ONCOPROTEIN; PROTEIN INHIBITOR;

ARTICLE; BURKITT LYMPHOMA; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA BINDING; DNA PROBE; DRUG IDENTIFICATION; DRUG STRUCTURE; EPITHELIUM CELL; EPSTEIN BARR VIRUS; FLUORESCENCE POLARIZATION; GENE REPRESSION; HIGH THROUGHPUT SCREENING; INFECTION; LYMPHOID CELL; LYMPHOMA CELL; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; VIRUS GENOME; VIRUS INHIBITION;

CELL LINE, TUMOR; DNA; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FLUORESCENCE POLARIZATION; GENE DOSAGE; HERPESVIRUS 4, HUMAN; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; PLASMIDS; PROTEIN BINDING; SMALL MOLECULE LIBRARIES; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC;

HUMAN HERPESVIRUS 4;

EID: 78650113600     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057110379154     Document Type: Article

References (39)

1. Rickinson AB, Kieff E.: Epstein-Barr Virus. Philadelphia: Wolters Kluwer Health / Lippincott Williams & Wilkins, 2007.
2. Kieff E.: Epstein-Barr Virus and Its Replication. Philadelphia: Wolters Kluwer Health / Lippincott Williams & Wilkins, 2007.
3. Thorley-Lawson DA, Gross A.: Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004 ; 350: 1328-1337.
4. Joseph AM, Babcock GJ, Thorley-Lawson DA: EBV persistence involves strict selection of latently infected B cells. J Immunol 2000 ; 165: 2975-2981.
5. Decker LL, Klaman LD, Thorley-Lawson DA: Detection of the latent form of Epstein-Barr virus DNA in the peripheral blood of healthy individuals. J Virol 1996 ; 70: 3286-3289.
6. Shibata D., Weiss LM: Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol 1992 ; 140: 769-774.
7. Fahraeus R., Fu HL, Ernberg I., Finke J., Rowe M., Klein G., et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 1988 ; 42: 329-338.
8. Young LS, Dawson CW, Clark D., Rupani H., Busson P., Tursz T., et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 1988 ; 69 (pt 5). 1051-1065.
9. Izumi KM: Epstein-Barr virus signal transduction and B-lymphocyte growth transformation. Prog Mol Subcell Biol 2004 ; 36: 269-288.
10. Young LS, Rickinson AB: Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004 ; 4: 757-768.
11. Gottschalk S., Rooney CM, Heslop HE: Post-transplant lymphoproliferative disorders. Annu Rev Med 2005 ; 56: 29-44.
12. Soni V., Cahir-McFarland E., Kieff E.: LMP1 TRAFficking activates growth and survival pathways. Adv Exp Med Biol 2007 ; 597: 173-187.
13. Leight ER, Sugden B.: EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus. Rev Med Virol 2000 ; 10: 83-100.
14. Wang J., Sugden B.: Origins of bidirectional replication of Epstein-Barr virus: models for understanding mammalian origins of DNA synthesis. J Cell Biochem 2005 ; 94: 247-256.
15. Sugden B., Leight ER: EBV's plasmid replicon: an enigma in cis and trans. Curr Top Microbiol Immunol 2001 ; 258: 3-11.
16. Lindner SE, Sugden B.: The plasmid replicon of Epstein-Barr virus: mechanistic insights into efficient, licensed, extrachromosomal replication in human cells. Plasmid 2007 ; 58: 1-12.
17. Yin Q., Flemington EK: siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBVdependent tumor cells. Virology 2006 ; 346: 385-393.
18. Kennedy G., Komano J., Sugden B.: Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc Natl Acad Sci U S A 2003 ; 100: 14269-14274.
19. Rawlins DR, Milman G., Hayward SD, Hayward GS: Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell 1985 ; 42: 859-868.
20. Yoshioka M., Crum MM, Sample JT: Autorepression of Epstein-Barr virus nuclear antigen 1 expression by inhibition of pre-mRNA processing. J Virol 2008 ; 82: 1679-1687.
21. Altmann M., Pich D., Ruiss R., Wang J., Sugden B., Hammerschmidt W.: Transcriptional activation by EBV nuclear antigen 1 is essential for the expression of EBV's transforming genes. Proc Natl Acad Sci U S A 2006 ; 103: 14188-14193.
22. Nilsson T., Zetterberg H., Wang YC, Rymo L.: Promoter-proximal regulatory elements involved in OriP-EBNA1-independent and -dependent activation of the Epstein-Barr virus C promoter in B-lymphoid cell lines. J Virol 2001 ; 75: 5796-5811.
23. Dresang LR, Vereide DT, Sugden B.: Identifying sites bound by Epstein-Barr virus nuclear antigen 1 (EBNA1) in the human genome: defining a position-weighted matrix to predict sites bound by EBNA1 in viral genomes. J Virol 2009 ; 83: 2930-2940.
24. De Clercq E: Antiviral drugs in current clinical use. J Clin Virol 2004 ; 30: 115-133.
25. Kleymann G: Novel agents and strategies to treat herpes simplex virus infections. Exp Opin Invest Drugs 2003 ; 12: 165-183.
26. Slobod KS, Taylor GH, Sandlund JT, Furth P., Helton KJ, Sixbey JW: Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system. Lancet 2000 ; 356: 1493-1494.
27. Chodosh J., Holder VP, Gan YJ, Belgaumi A., Sample J., Sixbey JW: Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype. J Infect Dis 1998 ; 177: 1194-1201.
28. Yarbro JW: Mechanism of action of hydroxyurea. Semin Oncol 1992 ; 19: 1-10.
29. Jiang R., Zhang JL, Satoh Y., Sairenji T.: Mechanism for induction of hydroxyurea resistance and loss of latent EBV genome in hydroxyurea-treated Burkitt's lymphoma cell line Raji. J Med Virol 2004 ; 73: 589-595.
30. Owicki JC: Fluorescence polarization and anisotropy in high throughput screening: perspectives and primer. J Biomol Screen 2000 ; 5: 297-306.
31. Rishi V., Potter T., Laudeman J., Reinhart R., Silvers T., Selby M., et al. A high-throughput fluorescence-anisotropy screen that identifies small molecule inhibitors of the DNA binding of B-ZIP transcription factors. Anal Biochem 2005 ; 340: 259-271.
32. Kiessling A., Sperl B., Hollis A., Eick D., Berg T.: Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. Chem Biol 2006 ;13: 745-751.
33. Frangioni JV, Neel BG: Solubilization and purification of enzymatically active glutathione S-transferase (pGEX) fusion proteins. Anal Biochem 1993 ; 210: 179-187.
34. Bochkarev A., Barwell JA, Pfuetzner RA, Bochkareva E., Frappier L., Edwards AM: Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA. Cell 1996 ;84: 791-800.
35. Ambinder RF, Shah WA, Rawlins DR, Hayward GS, Hayward SD: Definition of the sequence requirements for binding of the EBNA-1 protein to its palindromic target sites in Epstein-Barr virus DNA. J Virol 1990 ; 64: 2369-2379.
36. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999 ; 4: 67-73.
37. Lipinski CA, Lombardo F., Dominy BW, Feeney J.: Experimental and computation approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 1997 ; 23: 3-25.
38. Motlekar N., Diamond SL, Napper AD: Evaluation of an orthogonal pooling strategy for rapid high-throughput screening of proteases. Assay Drug Dev Technol 2008 ; 6: 395-405.
39. Ruf IK, Moghaddam A., Wang F., Sample J.: Mechanisms that regulate Epstein-Barr virus EBNA-1 gene transcription during restricted latency are conserved among lymphocryptoviruses of Old World primates. J Virol 1999 ; 73: 1980-1989.